You are here

Article info

Article menu
Download PDFPDF
Neurological dilemmas
Switching patients at high risk of PML from natalizumab to another disease-modifying therapy

Authors

  • Gavin Giovannoni Department of Neurosciences, Blizard Institute, Barts and The London School of Medicine and Dentistry, London, UK Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, UK PubMed articlesGoogle scholar articles
  • Monica Marta Department of Neurosciences, Blizard Institute, Barts and The London School of Medicine and Dentistry, London, UK Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, UK PubMed articlesGoogle scholar articles
  • Angharad Davis Department of Neurosciences, Blizard Institute, Barts and The London School of Medicine and Dentistry, London, UK Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, UK PubMed articlesGoogle scholar articles
  • Benjamin Turner Department of Neurosciences, Blizard Institute, Barts and The London School of Medicine and Dentistry, London, UK Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, UK PubMed articlesGoogle scholar articles
  • Sharmilee Gnanapavan Department of Neurosciences, Blizard Institute, Barts and The London School of Medicine and Dentistry, London, UK Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, UK PubMed articlesGoogle scholar articles
  • Klaus Schmierer Department of Neurosciences, Blizard Institute, Barts and The London School of Medicine and Dentistry, London, UK Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, UK PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Gavin Giovannoni, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London, 4 Newark Street, London E1 2AT, UK; g.giovannoni{at}qmul.ac.uk
View Full Text

Citation

Giovannoni G, Marta M, Davis A, et al
Switching patients at high risk of PML from natalizumab to another disease-modifying therapy
Practical Neurology 2016;16:389-393.

Publication history

  • Accepted March 28, 2016
  • First published April 25, 2016.
Online issue publication 
September 14, 2016

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Other content recommended for you